Cy

Prescription products · Product label record

Cystografin drug information

DIATRIZOATE MEGLUMINE
BRACCO DIAGNOSTICS INC · INTRAVENOUS

Product NDC: 0270-0149

Join the community
CommunityExperiencesReviewsDrug database
Source label information, not individualized medical advice. This record applies to the product and labeler shown below. Compare the exact formulation, strength and country with your package and the current source label.
Generic nameDIATRIZOATE MEGLUMINE
Labeler / manufacturerBRACCO DIAGNOSTICS INC
RouteINTRAVENOUS
Drug classDrug class not supplied in source label
Product NDC0270-0149
Label effective date2025-11-23

Official product label reference

Cystografin — BRACCO DIAGNOSTICS INC

This page contains 11 source sections for DIATRIZOATE MEGLUMINE, intravenous route. Label set 7496d736-9f7d-4136-ad5d-b24c7803c21b, version 7.

Retrieved 2026-10-02 · openFDA dataset updated 2026-10-02 · Check the current DailyMed label

Label records can cover multiple strengths or package sizes. A label listing does not by itself establish FDA approval or current market availability. Check the source and application history for this specific product.

Uses described in the label

INDICATION Cystografin is indicated for retrograde cystourethrography.
Dosage and administration — label text
DOSAGE AND ADMINISTRATION Preparation of the patient: Appropriate preparation is desirable for optimal results. A laxative the night before the examination and a low residue diet the day before the procedure are recommended. Dosage: The dose for retrograde use in cystography and voiding cystourethrography ranges from 25 to 300 mL depending on the age of the patient and the degree of bladder irritability; amounts greater than 300 mL may be used if the bladder capacity allows. Best results are obtained when the bladder is filled with the contrast agent. If desired, the preparation may be diluted with sterile water or sterile saline as indicated in the table below. Administration: After sterile catheterization, the bladder should be filled to capacity with Cystografin using a suitable sterile administration set. Care should be taken to avoid using excessive pressure. The presence of bladder discomfort or reflux and/or spontaneous voiding usually indicates that the bladder is full. Radiography: The commonly employed radiographic techniques should be used. A scout film is recommended before the contrast agent is administered. Dilution Table USE DILUTED SOLUTIONS IMMEDIATELY 100 mL Bottle Sterile Water or Sterile Saline Added % Diatrizoate Meglumine w/v % Organically Bound Iodine w/v Total Volume 0 mL 30.0 14.1 100 mL 25 mL 24.0 11.3 125 mL 50 mL 20.0 9.4 150 mL 67 mL 18.0 8.5 167 mL 300 mL Bottle Sterile Water or Sterile Saline Added 0 mL 30.0 14.1 300 mL 50 mL 25.7 12.1 350 mL Table text from source: Dilution Table | USE DILUTED SOLUTIONS IMMEDIATELY | 100 mL Bottle | | Sterile Water or Sterile Saline Added | % Diatrizoate Meglumine w/v | % Organically Bound Iodine w/v | Total Volume | 0 mL | 30.0 | 14.1 | 100 mL | 25 mL | 24.0 | 11.3 | 125 mL | 50 mL | 20.0 | 9.4 | 150 mL | 67 mL | 18.0 | 8.5 | 167 mL | 300 mL Bottle | | Sterile Water or Sterile Saline Added | | 0 mL | 30.0 | 14.1 | 300 mL | 50 mL | 25.7 | 12.1 | 350 mL
Contraindications
CONTRAINDICATIONS This preparation is contraindicated in patients with a hypersensitivity to salts of diatrizoic acid.
Warnings
WARNINGS Severe sensitivity reactions are more likely to occur in patients with a personal or family history of bronchial asthma, significant allergies, or previous reactions to contrast agents. A history of sensitivity to iodine per se or to other contrast agents is not an absolute contraindication to the use of diatrizoate meglumine, but calls for extreme caution in administration.
Adverse reactions
ADVERSE REACTIONS Retrograde genitourinary procedures may cause such complications as hematuria, perforation of the urethra or bladder, introduction of infection into the genitourinary tract, and oliguria or anuria. If intravasation of this drug occurs, the reactions which may be associated with intravenous administration may possibly be encountered. Hypersensitivity or anaphylactoid reactions may occur. Severe reactions may be manifested by edema of the face and glottis, respiratory distress, convulsions or shock; such reactions may prove fatal unless promptly controlled by such emergency measures as maintenance of a clear airway and immediate use of oxygen and resuscitative drugs. Endocrine: Thyroid function tests indicative of hypothyroidism or transient thyroid suppression have been uncommonly reported following iodinated contrast media administration to adult and pediatric patients, including infants. Some patients were treated for hypothyroidism.
Unclassified section
For retrograde cystourethrography Not intended for intravascular injection Revised June 2024 Rx only Manufactured for Bracco Diagnostics Inc. Princeton, NJ 08540 by Patheon Italia S.p.A. 03013 Ferentino (Italy) Table text from source: | Revised June 2024 | | Rx onlyManufactured for Bracco Diagnostics Inc. Princeton, NJ 08540by Patheon Italia S.p.A. 03013 Ferentino (Italy)
Product description
DESCRIPTION Cystografin is a radiopaque contrast agent supplied as a sterile, clear, colorless to pale yellow, mobile or slightly viscous solution. Each mL provides 300 mg diatrizoate meglumine with 0.4 mg edetate disodium as a sequestering agent. Each mL of solution also contains approximately 141 mg organically bound iodine. At the time of manufacture, the air in the container is replaced by nitrogen. The preparation should be protected from strong light.
Precautions
PRECAUTIONS Safe and effective use of this preparation depends upon proper dosage, correct technique, adequate precautions, and readiness for emergencies. Retrograde cystourethrography should be performed with caution in patients with a known active infectious process of the urinary tract. Sterile technique should be employed in administration. During administration, care should be taken to avoid excessive pressure, rapid or acute distention of the bladder, and trauma. Contrast agents may interfere with some chemical determinations made on urine specimens; therefore, urine should be collected before administration of the contrast medium or two or more days afterwards. Pregnancy—Teratogenic Effects: Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin should be administered to a pregnant woman only if clearly needed.
Teratogenic effects
Pregnancy—Teratogenic Effects: Animal reproduction studies have not been conducted with diatrizoate meglumine injection. It is also not known whether diatrizoate meglumine injection can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Cystografin should be administered to a pregnant woman only if clearly needed.
Supply and packaging
HOW SUPPLIED Cystografin (Diatrizoate Meglumine Injection USP 30%) is available in 200 mL and 400 mL bottles containing 100 mL and 300 mL of Cystografin respectively with sufficient capacity for dilution up to 167 mL and 350 mL respectively. Storage Store at 20-25°C (68-77°F) [See USP]. Protect from light. Also Available Cystografin Dilute (Diatrizoate Meglumine Injection USP 18%) is also available, as a 300 mL fill in a 400 mL bottle.
Storage and handling
Storage Store at 20-25°C (68-77°F) [See USP]. Protect from light.

Official sources and product identifiers

Substances listed: DIATRIZOATE MEGLUMINE

Package NDC codes

0270-0149-60, 0270-0149-57

Further research and background

These are external searches for related information. Research, encyclopedia and news articles have not been imported into this product record.

Coverage and corrections

The text is extracted from a US structured product label. Tables are represented as text where supplied; formatting and illustrations may be lost. A missing section does not mean a risk is absent. This reference has not been independently reviewed by a clinician and is not a live safety-alert service.

Source retrieved 2026-10-02. Read the source policy.